Founded in 1849 and headquartered in New York, Pfizer is one of the world’s leading biopharmaceutical companies engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. The company has a vast portfolio of medicines and vaccines, which are known in the worldwide market for preventing and curing multifarious diseases effectively. As pioneers of innovation for over 170 years, the company is committed to using cutting-edge technologies and procedures to accelerate the development of new therapies and treatments, with an aim to redefine healthcare.
As a global pharmaceutical conglomerate, Pfizer conducts extensive documentation for a wide variety of processes, including clinical trials, drug discovery, quality assurance and control, risk assessment and many more.
Traditionally, before integrating with the MSB platform, the company used to follow a pen-and-paper approach to fulfil all its documentation requirements, wherein all the experimental data used to be recorded in paper lab notebooks. A single drug discovery project generated piles of documents, that used to be manually signed, compiled and stored as a proof of discovery and for patent protection reasons. This manual, cumbersome process had taken a toll on the company’s operational efficiency, as the following challenges surfaced:
Getting the paper documents of an experiment signed and witnessed involved coordination between multiple stakeholders and continuous repetition of the print-sign-scan-fax cycle. This severely impacted the turnaround time and scientists had to wait for a few days before actually processing their experiments. As a result, the drug development process was delayed, which in turn deferred the delivery of treatments into the market.
The company incurred mammoth expenditure on printing, scanning, faxing, couriering and maintaining documents. The cost of resources deployed to conduct these mundane tasks was also a significant, unnecessary expense, and the pharmaceutical giant wanted to do away with these profit-eating costs.
The lab personnel spent most of their precious hours in conducting the routine paper work, which left them exhausted and thereby took a toll on their productivity levels.
The delay caused by paper processing led to various compliance issues.
Pfizer was actively looking for a scalable solution which could efficiently address the above challenges & facilitate seamless information sharing throughout the organisation.
As one of the leading eSignature solutions providers, MSB Docs was chosen by Pfizer to streamline its growing documentation requirements and to improve its signing and approval process. A seamless integration of Pfizer’s Chemistry Electronic Notebooks (CeN) was done with MSB’s electronic Signatures in the following manner:
Thus, all the time-consuming, paper-based processes at Pfizer were conveniently automated and converted into simple, digital signing processes.
The integration with MSB Docs has proved to be immensely valuable for the pharma leader. Besides generating significant cost savings, the team at Pfizer is now able to work yet more efficiently, thus creating and delivering breakthrough therapies to people in a timely manner. Precisely, MSB Docs has helped Pfizer in realizing the following benefits:
Increased speed, quality & agility of the drug development process
Increased efficiency in documentation, signing procedures and records management